Modality
Peptide
MOA
CDK2i
Target
GIP-R
Pathway
NF-κB
Meso
Development Pipeline
Preclinical
Apr 2018
→ Feb 2028
PreclinicalCurrent
NCT07964391
2,632 pts·Meso
2018-04→2025-06·Not yet recruiting
NCT03142376
2,152 pts·Meso
2021-04→2028-02·Completed
4,784 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-0610mo agoInterim· Meso
2028-02-051.9y awayInterim· Meso
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Not yet…
Preclinical
Complet…
Catalysts
Interim
2025-06-06 · 10mo ago
Meso
Interim
2028-02-05 · 1.9y away
Meso
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07964391 | Preclinical | Meso | Not yet recr... | 2632 | EDSS |
| NCT03142376 | Preclinical | Meso | Completed | 2152 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R |